Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark surveyRuben A. Mesa, John Mascarenhas, Carole B. Miller et al.|BMC Cancer|2016Cited by 194
Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark surveyRuben A. Mesa, John Mascarenhas, Ahmad Naim et al.|Cancer|2016Cited by 91
Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United StatesRuben A. Mesa, Brady L. Stein, Ralph V. Boccia et al.|Clinical Lymphoma Myeloma & Leukemia|2018Cited by 39
Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United StatesMichael R. Grunwald, Ruben A. Mesa, Brady L. Stein et al.|Clinical Lymphoma Myeloma & Leukemia|2018Cited by 37
Hydroxyurea Treatment History and Quality of Life in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United StatesRuben A. Mesa, James K. Mangan, Carole B. Miller et al.|Blood|2015Cited by 5